Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.

作者: Illarion V. Turko , Stephen A. Ballard , Sharron H. Francis , Jackie D. Corbin

DOI: 10.1124/MOL.56.1.124

关键词:

摘要: The cGMP-binding cGMP-specific phosphodiesterase (PDE5) degrades cGMP and regulates the intracellular level of in many tissues, including smooth muscle corpus cavernosum penis. Sildenafil (Viagra), a specific PDE5 inhibitor, promotes penile erection by blocking activity PDE5, which causes to accumulate cavernosum. In present study, sildenafil, like other inhibitors, stimulates binding allosteric sites interacting at catalytic site this enzyme, but drug does not compete with for sites. Both sildenafil zaprinast are competitive inhibitors double-inhibition analysis shows that these two added together interact mutually exclusive manner. After site-directed mutagenesis each 23 conserved amino acid residues domain pattern changes IC50 values or UK-122764 is similar found zaprinast. However, among three exhibits most affinity cGMP, implying interactions domain. This may explain part stronger inhibitory potency wild-type compared [sildenafil (Ki = 1 nM) > 5 130 nM)]. much higher than itself (Km 2000 nM). It concluded such as Tyr602, His607, His643, Asp754 form important because acids all mammalian PDEs, selectivity likely be provided nonconserved residue

参考文章(35)
T. J. McMahon, L. J. Ignarro, P. J. Kadowitz, Influence of Zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed Journal of Applied Physiology. ,vol. 74, pp. 1704- 1711 ,(1993) , 10.1152/JAPPL.1993.74.4.1704
S.H. Francis, T.M. Lincoln, J.D. Corbin, Characterization of a novel cGMP binding protein from rat lung. Journal of Biological Chemistry. ,vol. 255, pp. 620- 626 ,(1980) , 10.1016/S0021-9258(19)86221-X
Michael Czarniecki, Ho-Sam Ahn, Edmund J. Sybertz, Chapter 7. Inhibitors of Types I and V Phosphodiesterase: Elevation of cGMP as a Therapeutic Strategy Annual Reports in Medicinal Chemistry. ,vol. 31, pp. 61- 70 ,(1996) , 10.1016/S0065-7743(08)60446-7
M.K. Thomas, S.H. Francis, J.D. Corbin, Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. Journal of Biological Chemistry. ,vol. 265, pp. 14964- 14970 ,(1990) , 10.1016/S0021-9258(18)77210-4
L.M. McAllister-Lucas, W.K. Sonnenburg, A Kadlecek, D Seger, H.L. Trong, J.L. Colbran, M.K. Thomas, K.A. Walsh, S.H. Francis, J.D. Corbin, The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone. Journal of Biological Chemistry. ,vol. 268, pp. 22863- 22873 ,(1993) , 10.1016/S0021-9258(18)41607-9
A L Harris, P J Silver, R G Bentley, M H Perrone, B M Lemp, L T Hamel, Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle. Journal of Pharmacology and Experimental Therapeutics. ,vol. 249, pp. 394- 400 ,(1989)
D. A. Braner, J. R. Fineman, R. Chang, S. J. Soifer, M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. American Journal of Physiology-heart and Circulatory Physiology. ,vol. 264, ,(1993) , 10.1152/AJPHEART.1993.264.1.H252
F. Ichinose, C. Adrie, W. E. Hurford, W. M. Zapol, Prolonged pulmonary vasodilator action of inhaled nitric oxide by Zaprinast in awake lambs. Journal of Applied Physiology. ,vol. 78, pp. 1288- 1295 ,(1995) , 10.1152/JAPPL.1995.78.4.1288
T M Lincoln, P Komalavilas, T L Cornwell, Pleiotropic regulation of vascular smooth muscle tone by cyclic GMP-dependent protein kinase. Hypertension. ,vol. 23, pp. 1141- 1147 ,(1994) , 10.1161/01.HYP.23.6.1141